Changing paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy-Reference-Cited by-同舟云学术

Changing paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy

Published:2019-04-09 Issue:1 Volume:15 Page:125-130
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Matveev V. B.¹^ORCID,Volkova M. I.¹^ORCID,Olshanskaya A. S.²^ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia ; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference26 articles.

1. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95.

2. Cella, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019 Feb; 20(2): 297-310.

3. Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015;21:1071-7.

4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.

5. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27: 1280-9.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent;Current Pharmaceutical Design;2023-11

2. Does sunitinib still have a place in the current recommendations for the systemic treatment of advanced renal cell carcinoma?;Meditsinskiy sovet = Medical Council;2021-08-07